Extrawell Pharmaceutical Holdings (HKSE:00858) EPS without NRI: HK$-0.16 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Extrawell Pharmaceutical Holdings EPS without NRI?

Extrawell Pharmaceutical Holdings HKSE:00858 EPS without NRI is HK$-0.16 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 786 Drug Manufacturers companies, Extrawell Pharmaceutical Holdings ranks worse than 95.29% on this metric.

Extrawell Pharmaceutical Holdings's earnings per share without non-recurring items for the six months ended in Mar. 2026 was HK$-0.10. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was HK$-0.16.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -55.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -33.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Extrawell Pharmaceutical Holdings's EPS without NRI or its related term are showing as below:

HKSE:00858' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75.4   Med: -12.6   Max: 58.7
Current: -55.4

During the past 13 years, Extrawell Pharmaceutical Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 58.70% per year. The lowest was -75.40% per year. And the median was -12.60% per year.

HKSE:00858's 3-Year EPS without NRI Growth Rate is ranked worse than
95.29% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.65 vs HKSE:00858: -55.40

Extrawell Pharmaceutical Holdings's EPS (Diluted) for the six months ended in Mar. 2026 was HK$-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$-0.39.

Extrawell Pharmaceutical Holdings's EPS (Basic) for the six months ended in Mar. 2026 was HK$-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$-0.39.


Extrawell Pharmaceutical Holdings  (HKSE:00858) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Extrawell Pharmaceutical Holdings EPS without NRI Related Terms


Extrawell Pharmaceutical Holdings EPS without NRI Historical Data

* Premium members only.

The historical data trend for Extrawell Pharmaceutical Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Extrawell Pharmaceutical Holdings EPS without NRI Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 -0.03 0.02 -0.17

Extrawell Pharmaceutical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 -0.06 -0.10

HKSE:00858 vs ZTS: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's PE Ratio without NRI falls into.



Extrawell Pharmaceutical Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of HK$-0.16 mean?
Extrawell Pharmaceutical Holdings (HKSE:00858) has a EPS without NRI of HK$-0.16 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Extrawell Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Extrawell Pharmaceutical Holdings ranks #749 out of 786 companies in the Drug Manufacturers industry, placing it in the top 95.3%.
Is Extrawell Pharmaceutical Holdings' EPS without NRI too high?
Extrawell Pharmaceutical Holdings' current EPS without NRI is HK$-0.16. Based on the distribution chart, Extrawell Pharmaceutical Holdings ranks #749 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Extrawell Pharmaceutical Holdings' EPS without NRI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Extrawell Pharmaceutical Holdings ranks #749 out of 786 companies for EPS without NRI. This places Extrawell Pharmaceutical Holdings in the lower half of its industry. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Extrawell Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current EPS without NRI is HK$-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 68% above its estimated fair value. The current EPS without NRI is HK$-0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current EPS without NRI is HK$-0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Extrawell Pharmaceutical Holdings Business Description

Address 979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.